Our Focus

Ascletis focus on breakthrough therapies for HBV clinical cure with subcutaneously injected PD-L1 antibody - ASC22 and Pegasys® as cornerstone drugs. 



HBV Clinical Cure: ASC22 mechanism

image.png


Prolonged activation of T cells leads to high expression of PD-1. By blocking the connection between PD-1 and PDL-1 through PD-1 antibodies or PD-L1 antibodies, T-cells can remain activated and exert immune functions, ultimately leading to clinical cure.

图片4.jpg




In the area of chronic hepatitis C, Ascletis has twoall-oral regimen, among which ASCLEVIR®/GANOVO®regimen has been approved for marketing for marketing in China by National Medical Products Administration (NMPA).


丙肝靶点图.jpg




Publications


Title

Venue

Type

Date

Efficacy and safety of ravidasvir plus   sofosbuvir in patients with chronic hepatitis C infection without cirrhosis   or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage,   open-label, multicentre, single arm, phase 2/3 trial

The Lancet 

Gastroenterology & Hepatology

Paper

2021

First clinical study using HCV protease inhibitor danoprevir to treat COVID-19 patients

 Medicine

Paper

2020

Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China

Journal of Clinical and Translational Hepatology

Paper

2019

Efficacy and  safety of 12-week interferon-based danoprevir regimen in patients with  genotype 1 chronic hepatitis C

Journal of Clinical and Translational   Hepatology

Paper

2019

Twelve-week  Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin for non- cirrhotic  HCV genotype 1 patients: A phase 2 study

Journal of Gastroenterology and Hepatology

Paper

2018

Ritonavir-boosted  danoprevir plus peginterferon alfa-2a and ribavirin in Asian chronic  hepatitis C patients with or without cirrhosis

Journal of Gastroenterology and Hepatology

Paper

2016

DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4

Liver International

Paper

2015

All-oral, 12-week  ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100%  svr12 in treatment-naive noncirrhotic hcv genotype 1 patients with  resistance-associated substitutions of a phase 2/3 clinical trial in China

Journal of Hepatology

Poster

2019

12 week Ravidasvir plus ritonavir-boosted Danoprevir and ribavirin achieves 99% SVR12 in treatment-naı ¨ve non- cirrhotic HCV GT1 patients: Subanalysis of phase 2/3 clinical trial in China

Hepatol Int

Poster

2019

The Effcacy and  Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and  Ribavirin in Treatment-Naïve Non-Cirrhotic HCV Genotype 1 Patients : Results  from a Phase 2/3 Clinical Trial in China

HEPATOLOGY

Poster

2018

MAKALU:  Twelve-week of treatment with Ritonavir-boosted Danoprevir Pluzs Peginterferon  and Ribavirin produces 96% SVR12 in HCV Genotype 1-Infected Non-Cirrhotic  Chinese Patients

Hepatol Int

Poster

2017